Endometrial Biopsy Billing in Fertility Practices

Endometrial biopsy is one of the most frequently performed in-office procedures in reproductive endocrinology, yet it is also one of the most frequently miscoded, misbilled, and misrouted between major medical and fertility benefits. A single procedure note can support three different reimbursement pathways depending on the indication, the payer, and whether an associated pathology specimen was submitted. This guide covers everything a fertility billing specialist needs to know: correct CPT code selection, diagnosis code strategy, benefit routing, pathology billing, modifier use, and how to prevent the most common denial patterns this procedure generates.

What Is Endometrial Biopsy in the Fertility Context?

In a reproductive endocrinology practice, endometrial biopsy — also called endometrial sampling or pipelle biopsy — serves several distinct clinical purposes: evaluating abnormal uterine bleeding before initiating ART cycles; ruling out endometrial hyperplasia or malignancy in patients with risk factors such as PCOS or obesity; obtaining a specimen for ERA (Endometrial Receptivity Array) testing; performing an elective endometrial scratch to attempt enhanced embryo implantation; and diagnosing chronic endometritis as part of a recurrent implantation failure workup. Each of these indications carries a different primary diagnosis code, and that code largely determines whether the claim routes to the patient's major medical benefit or to a fertility-specific benefit carve-out. Getting the indication right is not optional — it is the foundation of the entire claim.

CPT Code Selection for Endometrial Biopsy

The primary CPT code for in-office endometrial biopsy in a fertility practice is 58100: "Endometrial sampling (biopsy) with or without endocervical sampling, without cervical dilation, any method." This code covers the standard pipelle biopsy, Novak curette, or Vabra aspiration performed in the office setting without dilation. The code carries a 0-day global period under the Medicare Physician Fee Schedule, which means no pre- or post-operative services are bundled into the payment — separately identifiable evaluation and management services on the same day may be billed with modifier 25 appended to the E/M code.

If cervical dilation is required before the biopsy can be obtained, CPT 57800 (Dilation of cervical canal, instrumental, separate procedure) is sometimes argued separately, but most commercial payers bundle 57800 into 58100 when dilation is performed as a step within the same biopsy procedure. Do not unbundle 57800 unless you have payer-specific written guidance or documented evidence that the dilation required significantly greater effort independent of the biopsy.

CPT 58558 (Hysteroscopy, surgical; with endometrial sampling, biopsy) is a facility-based code for biopsy obtained under direct hysteroscopic visualization. It is not interchangeable with 58100. If your REI physician performs a pipelle biopsy in the office and you code 58558, you have upcoded — that is a compliance violation in addition to a claim error. Conversely, if the physician documents that she placed a hysteroscope and obtained a directed biopsy under direct visualization, then 58558 is correct and 58100 would undercode the procedure. The documentation must make the technique unambiguous before any code selection is finalized.

CPT and Pathology Code Reference Table

ICD-10 Code Selection: Matching Diagnosis to Indication

The diagnosis code is the single most important variable determining how the claim is processed, what benefit the payer applies, and whether the service is covered at all. Endometrial biopsy in fertility patients is performed for at least five distinct clinical indications, and each requires a different primary ICD-10 code.

For evaluation of abnormal uterine bleeding before ART, use N93.0 (Postcoital and contact bleeding), N92.0 (Excessive and frequent menstruation with regular cycle), N92.1 (Excessive and frequent menstruation with irregular cycle), or N93.8 (Other specified abnormal uterine and vaginal bleeding) depending on the symptom pattern. These codes route the claim to major medical, where endometrial biopsy is a covered diagnostic service in virtually every commercial plan under standard gynecology benefits.

For evaluation of suspected endometrial hyperplasia or polyp, use N85.00 (Endometrial hyperplasia, unspecified), N85.01 (Benign endometrial hyperplasia), N85.02 (Endometrial intraepithelial neoplasia [EIN]), or N84.0 (Polyp of corpus uteri) as appropriate. These are major medical diagnoses regardless of the patient's concurrent fertility treatment. The biopsy is a diagnostic procedure responding to a pathological finding — it should never be submitted with N97.x as the primary code when a pathological finding is the actual clinical indication.

For evaluation of chronic endometritis as part of a recurrent implantation failure (RIF) workup, use N71.1 (Chronic inflammatory disease of uterus) as the primary code, with a secondary infertility code for clinical context if the payer's claim form supports it. Chronic endometritis biopsy generates frequent denials when submitted under a fertility benefit with N97.x primary, because the biopsy is a diagnostic service for an infectious and inflammatory condition — not a fertility procedure per se.

For ERA biopsy (endometrial receptivity analysis) — where the specimen is sent for W-array gene expression analysis rather than standard histology — the most defensible primary code is N97.9 (Female infertility, unspecified) or the more specific infertility etiology code. ERA biopsy is a fertility-specific diagnostic step with no major-medical analog, so routing to the fertility benefit is appropriate. However, note that most fertility benefit managers do not include ERA as a covered line item within smart cycle bundles; confirm each payer's coverage position before submitting.

For endometrial scratch — a deliberate mechanical disruption of the endometrium before IVF to potentially improve implantation rates — the primary code is again N97.9 or the patient's specific infertility etiology code. Coverage is highly variable; many commercial payers classify endometrial scratch as investigational. Obtain prior authorization before performing this service if the patient expects coverage, and document patient financial responsibility discussions if the payer's medical policy categorizes the service as Category III or experimental.

Benefit Routing: Major Medical vs. Fertility Carve-Out

This is the area where fertility billing staff most commonly misroute endometrial biopsy claims. The rule is straightforward but requires consistent discipline: the indication drives the benefit, not the procedure name.

If the endometrial biopsy is performed to evaluate abnormal bleeding, hyperplasia, suspected polyp, or pathological endometrial finding — even if the patient is actively pursuing IVF — the claim belongs on the major medical benefit with the pathological diagnosis as primary. Submitting it to the fertility benefit manager (Progyny, WINFertility, Carrot Fertility, and others) will generate a denial because those benefits do not cover diagnostic services for gynecologic pathology. The patient's major medical deductible and coinsurance apply, and the claim should be routed accordingly from the start.

If the biopsy is performed specifically as a fertility-related service — ERA, endometrial scratch, or a protocol-mandated pre-transfer endometrial evaluation without an underlying pathological finding — and the patient has an active fertility benefit, submit to the fertility benefit first and be prepared for the medical policy review that frequently follows for ERA and endometrial scratch claims.

One common boundary case: the biopsy is ordered to rule out pathology before starting a new fertility cycle because a prior imaging study (saline infusion sonography or office hysteroscopy) showed a thickened endometrium or an uncharacterized intrauterine finding. In this scenario, the clinical indication is the pathological finding on imaging, not the fertility cycle itself. Route to major medical using the thickened endometrium finding (N85.8 or N85.00, depending on histological context) as primary. If imaging showed nothing abnormal and the biopsy is purely protocol-driven, route to the fertility benefit.

Pathology Specimen Billing

Whenever an endometrial biopsy specimen is submitted for histological analysis, CPT 88305 (Level IV surgical pathology, gross and microscopic examination) should be billed by the processing laboratory. The AMA's tissue descriptor list for CPT 88305 specifically includes "Endometrium, curettage or biopsy," making it the correct level code when a pipelle or curettage specimen is submitted for routine histology.

CPT 88309 (Level VI surgical pathology) is occasionally misused for endometrial specimens as an upcoding error. Level VI is reserved for complex neoplastic specimens requiring extensive sampling and multiple cassettes, such as uterine malignancies. A routine pipelle biopsy for hyperplasia surveillance or infertility evaluation does not meet Level VI criteria. If your in-house laboratory bills 88309 routinely for endometrial biopsies, this practice creates audit exposure and should be corrected prospectively.

When the biopsy specimen is sent to an outside reference laboratory, the fertility clinic typically does not bill any pathology component. The reference lab bills 88305 directly to the payer under its own NPI and tax ID. If the treating REI physician provides the formal pathology interpretation from slides prepared by the reference lab, then a professional component bill using 88305-26 may be supported, but only when the physician has documented a formal written interpretation separate from the clinical encounter note. Most fertility practices do not have this arrangement and should not bill 88305-26.

For ERA specimens specifically, the analysis is performed by the ERA laboratory (typically Igenomix/Igenomix-IVIRMA) and is not reported under CPT 88305. The ERA lab has its own proprietary billing for the gene expression analysis. The fertility clinic's role is limited to CPT 58100 for the biopsy procedure and specimen handling. Do not bill 88305 when the entire specimen is shipped to an ERA laboratory — no histological analysis is being performed by a pathologist.

Modifier Strategy for Same-Day Services

The 0-day global period for CPT 58100 simplifies modifier strategy considerably because there is no bundled pre- or post-operative visit period. However, several common same-day scenarios still require careful modifier application.

• Modifier 25 on E/M (same day as biopsy): Required when an E/M service is separately identifiable and medically necessary beyond the pre-procedure assessment. The E/M note must document a distinct history, clinical decision-making, and a plan independent of the biopsy procedure itself. A biopsy performed during a new patient consultation qualifies; a biopsy performed during a routine follow-up primarily for the biopsy itself typically does not.
• Modifier 59 (or XU/XS/XE/XP) on second procedure same day: Required when two distinct biopsy procedures occur on the same date of service and each has a separately documented clinical indication. Confirm whether the payer requires plain modifier 59 or prefers one of the X-modifier subsets — United Healthcare, for example, strongly prefers XU for distinctly unrelated services.
• Modifier 51 (multiple procedures): Not required for CPT 58100 when combined with an E/M; modifier 25 on the E/M is the correct approach. Modifier 51 may be relevant when 58100 is billed alongside another surgical procedure with a higher work value, to indicate the secondary procedure has a reduced reimbursement obligation under fee schedule rules.
• Modifier 26 (professional component): Applicable to pathology codes (88305-26) only when the fertility practice's physician provides the formal written pathology interpretation. Do not append modifier 26 to CPT 58100 itself — 58100 is a procedure code without a technical/professional split.
• No modifier needed if biopsy is billed alone: When 58100 is the only procedure on the claim and there is no same-day E/M, no modifier is required. Submit cleanly with the appropriate ICD-10 primary and secondary codes.

Common Denial Patterns and Prevention Strategies

Endometrial biopsy denials in fertility practices cluster around a predictable set of root causes. Identifying these patterns allows billing staff to build proactive edits into the pre-submission workflow rather than managing denials reactively after the claim has already aged.

• Denial: "Procedure not covered under fertility benefit" — Cause: a major-medical indication (hyperplasia, AUB, chronic endometritis) was routed to the fertility carve-out. Prevention: implement indication-driven benefit routing as a pre-billing edit. If the ICD-10 primary is anything other than N97.x or Z31.x, route to major medical before submission.
• Denial: "Duplicate claim" — Cause: two units of 58100 billed on the same DOS without modifier 59 or X-modifier for distinct procedures. Prevention: add a same-day duplicate procedure check to your clearinghouse edits and apply modifier 59/XU automatically when two units of 58100 appear on the same DOS.
• Denial: "Investigational / not medically necessary" — Cause: endometrial scratch submitted without prior authorization to a payer whose medical policy classifies the service as experimental. Prevention: check each payer's online medical policy for endometrial scratch before performing the service if coverage is expected; obtain PA and obtain signed patient financial responsibility agreement when PA is denied or when the payer's policy explicitly excludes the service.
• Denial: "Bundled with hysteroscopy" — Cause: CPT 58100 billed on the same date as 58558, which already includes endometrial sampling. Prevention: train coders to recognize that 58558 subsumes 58100; the two codes should never appear together on the same claim. If both were inadvertently billed, retract 58100 and resubmit 58558 only.
• Denial: "Missing or insufficient documentation" — Cause: claim lacks a signed procedure note with indication, technique, specimen handling disposition, and patient tolerance. Prevention: require a completed procedure note for every 58100 claim before it enters the billing queue; route to a documentation hold status if the note is not finalized within 48 hours of the procedure date.
• Denial: "Non-covered service — experimental" for ERA — Cause: ERA biopsy submitted to a payer without a specific ERA coverage policy; ERA is not yet covered by most commercial payers outside of certain fertility benefit managers. Prevention: verify ERA coverage at the benefits verification stage before scheduling, and collect ERA costs as self-pay if coverage cannot be confirmed.

Documentation Requirements for CPT 58100

A compliant endometrial biopsy procedure note must support the CPT code selection, the clinical indication, and the medical necessity of the service. Deficiencies in any of these areas are the most common cause of documentation-related denials and recoupment requests on audit. The following elements are required at minimum.

• Date and time of procedure and name of performing physician
• Patient consent documented (signed informed consent form or verbal consent noted in the chart)
• Clinical indication: specific reason for biopsy, tied to a diagnosable condition or documented fertility protocol requirement
• Technique: instrument used (e.g., Pipelle de Cornier, Novak curette, Karman cannula), number of passes, patient tolerance
• Findings: description of endometrial tissue obtained, estimated adequacy of specimen, any procedural complications or difficulties
• Specimen disposition: name of laboratory to which specimen was submitted; whether specimen was sent for standard histopathology (88305), ERA analysis (specify lab), or other specialized testing
• Physician signature with date and time of note completion
• If modifier 25 is used for a same-day E/M: the E/M note must document history, physical, and assessment/plan that are independently substantive and not simply restating the biopsy pre-procedure assessment

Quarterly Self-Audit Checklist for Endometrial Biopsy Claims

Given the frequency of this procedure in most REI practices and the multiple error vectors it presents, a quarterly review of a sample of endometrial biopsy claims is a practical quality-control measure. The audit should evaluate the following items for each claim in the sample.

• Is the primary ICD-10 code consistent with the clinical indication documented in the procedure note — not defaulted to N97.9 when a pathological finding is the actual indication?
• Is the claim routed to the correct benefit (major medical vs. fertility carve-out) based on the indication?
• If CPT 88305 was billed by an in-house lab, is CLIA certification current for high-complexity testing, and is Level IV (not Level VI) appropriate for the specimen submitted?
• If an E/M was billed on the same DOS with modifier 25, does the E/M note contain independently substantive content beyond the pre-procedure assessment?
• If two units of 58100 appear on any claim in the sample, is modifier 59 or an X-modifier present, and are two distinct procedure notes on file for that DOS?
• Are endometrial scratch claims accompanied by a prior authorization number, or is a patient financial responsibility form on file if the service was performed as self-pay?
• For any denied claim in the audit sample, was an appeal filed within the payer's timely appeal window, and does the denial reason match one of the preventable patterns above?
• Is the performing provider's NPI and taxonomy code correctly linked to each claim — particularly important when the biopsy is performed by a midlevel under physician supervision and incident-to billing rules apply?

Incident-To Billing Considerations

In many fertility practices, nurse practitioners, physician assistants, or certified nurse midwives perform routine endometrial biopsies. When incident-to billing under the supervising physician's NPI is applied in a Medicare context, the CMS incident-to rules require that the supervising physician is present in the office suite (not necessarily the same room) during the service, that the service is an integral part of the physician's treatment plan, and that the service is of a type routinely performed in the office. Endometrial biopsy satisfies the last two criteria easily, but the presence requirement must be documented or the claim must be submitted under the midlevel's own NPI with the appropriate taxonomy code and at the applicable reimbursement rate (85% of the physician fee schedule for Medicare).

For commercial payers, incident-to rules vary significantly. Many commercial contracts do not follow CMS incident-to requirements and instead have their own credentialing and supervision policies. Verify each commercial payer's policy on midlevel provider billing before defaulting to the supervising physician's NPI for biopsies performed by midlevels. Incorrect NPI on the claim is a recoverable compliance error that can generate significant recoupment liability if discovered on audit.

Reimbursement Benchmarks

Under the 2026 Medicare Physician Fee Schedule, CPT 58100 is valued at approximately 1.66 total relative value units (RVUs), translating to roughly $59 to $68 at the national conversion factor depending on geographic adjustment. Commercial payer reimbursement for 58100 typically ranges from 110% to 180% of Medicare rates, placing in-network commercial reimbursement in the $65 to $120 range in most markets. Fertility-benefit-manager reimbursement for 58100 (when covered) varies by contract; some smart cycle bundles include biopsy at a bundled rate rather than a separately payable service, which is why confirming contract terms for this code specifically matters before assuming it will generate a separate allowable.

Practices that perform high volumes of endometrial biopsies — particularly those with active ERA testing programs or recurrent implantation failure clinics — should benchmark their collection rate for 58100 quarterly. A collection rate below 70% of billed charges (net of contractual adjustments) on this code suggests systematic routing errors, documentation deficiencies, or denial patterns that have not been addressed. The per-claim dollar amount is modest, but at 10 or 20 biopsies per week, even a $20 average leakage per claim compounds to significant annual revenue loss.

Summary

Endometrial biopsy billing appears deceptively simple — one code, one procedure, one visit. In practice, the correct claim requires a precise understanding of five distinct clinical indications, two or more possible benefit pathways, pathology billing dependencies, same-day modifier rules, midlevel billing compliance, and payer-specific coverage policies that range from fully covered to experimental depending on the indication. Practices that consistently get this right do so by building indication-specific routing logic into their pre-billing workflow, training clinical staff to document the indication and specimen disposition unambiguously in every procedure note, and auditing endometrial biopsy claims quarterly as a discrete line-item category rather than folding them into general gynecology claim reviews. Given its high frequency and modest per-claim reimbursement, this is a procedure where systematic accuracy at scale — not heroics on individual denials — is what drives collection performance.